Highlights
==========

1.  The microarray technique detected either up-regulated or down-regulated expression of 2189 genes in the striatum of prenatally METH-exposed rats.

2.  The microarray technique detected either up-regulated or down-regulated expression of 1344 genes in the hippocampus of prenatally METH-exposed rats.

3.  We examined the expression of 10 genes using the real-time PCR technique.

4.  Prenatally administered METH significantly alters the expression of the glucocorticoid nuclear receptor Nr3c1 mRNA within prefrontal cortex of rats.

5.  Prenatally administered METH significantly alters the expression of the cocaine- and amphetamine-regulated transcript prepropeptide, the tachykinin receptor 3 and dopamine receptor D3 mRNA within striatum of rats.

6.  Prenatally administered METH significantly alters the expression of the carboxylesterase 2 mRNA within the hippocampus of rats.

7.  Prenatally administered METH alters the expression of the trace amine-associated receptor mRNA within hippocampus of rats

8.  Both techniques, microarray and real-time PCR, showed altered expression of the tachykinin receptor 3 and dopamine receptor D3 mRNA within striatum of rats.

Introduction {#S1}
============

Methamphetamine (METH) is one of the most common "hard" drugs taken by pregnant women ([@B92]). It is also one of the most frequently used illicit drugs in the Czechia, Middle and Eastern Europe ([@B148]; [@B125]). Statistics show that only 17% of female drug abusers in the United States were primary METH users, but 38% had used it during pregnancy, because some drug-abused women replace other drugs for METH during pregnancy for its anorectic effect ([@B92]). METH is a powerfully addictive stimulant that metabolizes slowly resulting in the drug having a long-lasting high (8 to 24 h) ([@B92]). This might be the reason that makes it so popular. The National Institute of Drug Abuse (NIDA; part of NIH) in the United States decided to increase funding for studies testing the effects of METH administration during pregnancy. Research concerning the long-term effects of prenatal METH exposure is still in its infancy. Our laboratory specializes in investigating the effects of drugs (especially METH) on rat mothers and their progeny.

METH is an indirect agonist of monoamines, which works by disrupting multiple presynaptic and synaptic processes. The resultant increases in dopamine, norepinephrine, and serotonin contribute to its properties as well as inducing other central and peripheral effects ([@B144]; [@B86]). In low doses, METH can elevate mood and increase alertness, concentration and energy. At higher doses, it can induce psychosis, breakdown of skeletal muscle, seizures and bleeding in the brain. Chronic, high-dose use can precipitate unpredictable and rapid mood swings, prominent delusions and violent behavior. Chronic abuse is associated with serious health complications including deficits in attention, memory, and executive functions in humans ([@B15]). METH is known to have a high addiction liability (i.e., compulsive METH use) and dependence liability (i.e., withdrawal symptoms occur when METH use ceases) ([@B21]; [@B154]). METH travels through the bloodstream to the brain, where it readily crosses the blood-brain barrier ([@B26]; [@B14]). The similarity of the chemical structure of METH to monoamine neurotransmitters (dopamine and noradrenaline) determines its mechanism of action ([@B142]; [@B49], [@B108]). METH affects the function and trafficking of DAT. It leads to increased release of dopamine from presynaptic terminals, as well as synaptic vesicles ([@B141]). Methamphetamine interacts with Taar1 receptors and this interaction results in inhibition of dopamine uptake, induction of dopamine efflux, and promotion of dopamine transporter internalization. TAAR1 mediates methamphetamine-induced regulation of dopamine transporter function and trafficking in brain striatal synaptosomes ([@B160]; [@B117]). In Taar1-knock out mice sensitivity to amphetamine and methamphetamine was exacerbated ([@B82]; [@B2]; [@B117]). The neuropsychiatric complications might, in part, be related to drug-induced neurotoxic effects, which include damage to dopaminergic and serotonergic terminals, neuronal apoptosis, as well as activated astroglial and microglial cells in the brain ([@B15]).

METH present in a drug-abusing women's bloodstream, can pass through the placenta to a fetus and can also be secreted into breast milk ([@B156]). Amphetamines have vasoactive effects, which result in the restrictions of the supply of nutrients to a developing fetus, causing the anorectic symptoms often reported ([@B156]). Infants born from METH-abusing mothers were found to have significant growth reductions ([@B31]; [@B106]; [@B25]), cleft palate, cardiac defects ([@B106]; [@B25]), aggressive behavior ([@B35]; [@B25]), peer-related problems ([@B38]; [@B25]) and learning problems ([@B16]; [@B25]). Matera and colleagues reported severe brain malformations in a human infant exposed to amphetamine *in utero*, such as exencephaly, anomalies of gyria, and hemorrhage ([@B94]; [@B25]). Human infants exposed to methamphetamine *in utero* have tended to show a significant decrease in head circumference ([@B83]; [@B31]; [@B25]; [@B156]). Non-invasive studies of the brain using Echo or MRI have revealed intracranial hemorrhage ([@B31]; [@B25]) and volume decrease of subcortical area ([@B20]; [@B25]). The effects of METH-administered prenatally in clinical studies are summarized in [Table 1](#T1){ref-type="table"}.

###### 

The list of published results of clinical trials with METH-administered prenatally.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Etiopatogenetic factor**                                   **Effect**                                                                                                                                                                                                                **Author**
  ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Amphetamine administration during pregnancy                  Brain malformations, such as exencephaly, anomalies of gyria, and hemorrhage                                                                                                                                              [@B94]; [@B25]

  METH and amphetamine administration during pregnancy         At birth, 1, and 4 years: the mean weight, height, and head circumference below average\                                                                                                                                  [@B36]; [@B16]; [@B159]
                                                               Age 10: females, but not males, significantly shorter and lighter\                                                                                                                                                        
                                                               At 14--15 years: achievement in mathematics, Swedish language, and sports were statistically low                                                                                                                          

                                                               An increased rate of premature delivery and placental abruption                                                                                                                                                           [@B36], [@B37]; [@B159]

  METH, amphetamine, cocaine administration during pregnancy   Cleft lip and palate, heart defects, low birth weight, small head circumference, dead fetus, biliary atresia, undescended testicles, low body fat, premature birth                                                        [@B36]; [@B101]; [@B83]; [@B31]; [@B25]

  Perinatal administration of METH and cocaine                 Tachycardia, bradycardia, abnormal sleep, tremors                                                                                                                                                                         [@B101]

  METH administration during pregnancy                         Decreased fetal-growth, no congenital anomalies                                                                                                                                                                           [@B83]; [@B25]

  Drug administration during pregnancy                         Delayed development                                                                                                                                                                                                       [@B147]

  Maternal methamphetamine abuse                               Fetal and infant death                                                                                                                                                                                                    [@B140]

  METH and amphetamine administration during pregnancy         At 8 years: significant correlation between amount and duration of exposure prenatally and aggressive behavior and social adjustment                                                                                      [@B9]; [@B38]; [@B159]

  METH and amphetamine administration during pregnancy         Cleft, cardiac anomalies and fetal growth retardation                                                                                                                                                                     [@B106]; [@B159]; [@B25]

  METH administration during pregnancy                         Increased muscle tone, tremors, irritability, irregular sleep, impaired adaptability to stress                                                                                                                            [@B159]

  METH administration during pregnancy                         Smaller subcortical volumes and associated neurocognitive deficits, neurotoxicity to the developing brain                                                                                                                 [@B20]; [@B25]

  Pre-clinical trial: prenatal methamphetamine exposure        Reduced dopamine transporter density and reduced dopamine D2 receptors in the striatum, lower levels of serotonergic transporter density and vesicular monoamine transporter across striatal sub regions                  [@B19]

  METH administration during pregnancy                         Anorectic symptoms                                                                                                                                                                                                        [@B156]

  METH administration during pregnancy                         Subtle reductions in spatial performance in the Memory Island test                                                                                                                                                        [@B105]

  METH administration during pregnancy                         Increased emotional reactivity and anxious/depressed problems at ages 3 and 5 years; Attention-deficit/ hyperactivity disorder problems by age 5 years; Attention problems and withdrawn behavior at ages 3 and 5 years   [@B73]

  Prenatal METH and tobacco exposure                           Significantly reduced caudate nucleus volumes and cortical thickness increases in perisylvian and orbital-frontal cortices; subtle attentional deficits                                                                   [@B28]

  Prenatal exposure to METH                                    Significantly higher cognitive problems subscale scores than comparisons and were 2.8 times more likely to have cognitive problems scores that were above average                                                         [@B30]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Experimental studies demonstrated that administration of METH to pregnant rats leads to increased likelihood of abortion and maternal death ([@B3]; [@B93]). Pregnant rats who receive METH have a shorter gestation period and have fewer litters of young than control mothers ([@B90]; [@B91]). METH-administered prenatally increases infant mortality, reduces weight gain, delays development and slows down reflexes ([@B91]; [@B23]; [@B4]; [@B93]). Studies from our laboratory and others demonstrated that prenatal or neonatal exposure to METH seriously impairs the behavior of adult rats and their sensitivity to drugs ([@B125]). Also, our studies demonstrated that maternal addiction during gestation and/or lactation periods impairs maternal behavior, which in turn has adverse effects on pup development ([@B126],[@B127], [@B130]). Such impairment caused by prenatal METH exposure can be partially suppressed by cross-fostering with control rats, demonstrating the positive effect of good postnatal foster care ([@B57], [@B55]; [@B107]). On the other hand, maternal separation induces social stress and maternal physical stress, aggravating cognitive impairment and responses to stressors in the exposed offspring ([@B52], [@B51]). Thus, it seems that social factors, such as bad or good maternal care or maternal stress, can have significant influence on the development of rat offspring exposed to METH during gestation. In addition, one of our studies found that drug exposure during gestation may even influence second generation pups ([@B129], [@B132]).

There are several brain structures that are associated with drug addiction. The most important are mesolimbic, and mesocortical pathways ([@B113]) which includes the striatum, hippocampus and prefrontal cortex. Striatum coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward perception ([@B161]). The hippocampus plays important roles in the consolidation of information from short-term memory to long-term memory, and in spatial memory that enables navigation ([@B6]). The prefrontal cortex has been implicated in planning complex cognitive behavior, personality expression, decision making, and moderating social behavior ([@B162]). Various studies have found that prenatal exposure to psychostimulants results in enhanced responsiveness of mesostriatal monoaminergic projections ([@B12]; [@B41]). Given that our previous studies demonstrated changes in locomotor activity, cognition as well as social behavior ([@B39]; [@B131]), types of behavior that are associated with the above mentioned brain structures, the aim of the present study was to identify candidates for changes in the gene expression in the striatum, hippocampus and prefrontal cortex in adult rats in PD 80, whose mothers had been administered METH (5 mg/kg/day) during the entire gestation period.

Materials and Methods {#S2}
=====================

Animals and Housing {#S2.SS1}
-------------------

The procedures for animal experimentation utilized in this study were reviewed and approved by the Committee for Protection of Experimental Animals of Third faculty of Medicine and by Departmental Committee of Ministry of Education, Youth, and Sports and are in agreement with the Czech Government Requirements under the Policy of Humans Care of Laboratory Animals (no. 246/1992) and also comply with the regulations of the Ministry of Agriculture of the Czech Republic (no. 311/1997). Adult male (300--400 g) and female (250--300 g) Wistar rats from Charles River Laboratories International, Inc., were delivered by VELAZ (Prague, Czechia) and housed 4--5 per cage in a temperature-controlled (22--24.8°C) colony room with a standard 12 h light/dark cycle, lights on at 06.00 h. Animals were left undisturbed for 1 week with food and water *ad libitum*. After the acclimation period, the females were weighed and smeared using vaginal lavage to determine the phase of the estrous cycle. Females at the onset of the estrous phase of the estrous cycle were housed with sexually mature males for overnight (1 pair per cage) ([@B126],[@B127],[@B128],[@B129];[@B121]). On the following day, the females were smeared and returned to their previous home cages. The fertilization was assigned as Day 1 of gestation based on the presence of sperm in the vaginal smear. On Day 21 of gestation, the females were removed from the group cages and placed into maternity cages (1 female per cage). The day of the delivery was counted as PD 0. The number of pups in each litter was adjusted to 12. Whenever possible, the same numbers of male and female pups were kept in each litter. To avoid litter bias, pups were cross-fostered on PD 1 so that one mother usually raised three male and three female pups of her own and three male and three female pups from another mother (see below). On PD 21, animals were weaned and housed in groups separated by sex. The light/dark cycle of the animals was reversed with lights on at 18.00 h. Animals were left undisturbed until adulthood ([@B121]).

Drug Administration and Experimental Groups {#S2.SS2}
-------------------------------------------

For prenatal exposure, the pregnant dams were divided into two groups: the METH group and the SAL group. The females from the METH group were administered D-methamphetamine HCl (Sigma Aldrich, Czechia) at a dose of 5 mg/kg/day and volume of 1 ml/kg/day s.c. for the duration of the gestation period (i.e., from the first to the last day of gestation) ([@B126],[@B127],[@B129],[@B130]; [@B121]). This METH dose was chosen because it results in similar fetal brain drug concentrations to those found in human infants of METH-abusing women ([@B4]; [@B121]). This dose is also the standard dose used in our experiments ([@B126],[@B127],[@B129], [@B130], [@B132]; [@B121]). The females from the SAL group were administered 0.9% NaCl solution s.c. at the same time and in the same volume as METH. On PD 1, the offspring were marked according to the prenatal exposure using the intradermal application of black India ink; the METH group of prenatally affected offspring was marked in the left foot pad, and the SAL group of prenatally affected offspring was marked in the right foot pad.

Study Subjects {#S2.SS3}
--------------

Before we started the experiment in PD 80, the experimental animals (8 METH and 8 SAL rats) were weighed as were the parts of the brains from which the RNA was isolated. The isolation of total RNA (mixture of mRNA, tRNA, and rRNA) from the snap-frozen tissue was obtained in accordance with the published procedure by Zhu Shirley: Total RNA isolation and purification for microarray ([@B45]). The cerebral parts of experimental rats, striatum, hippocampus and prefrontal cortex, were obtained and stored in TRI reagent (Sigma-Aldrich, United States). The tissue was homogenized, centrifuged, washed with chloroform, and precipitated in isopropanol. Total RNA from the striatum, hippocampus and prefrontal cortex was used in the microarray and real-time PCR techniques.

Microarray Technique {#S2.SS4}
--------------------

The microarray technique was carried out using Genechip Rat Gene 2.0 ST Array (Affymetrix, United States) in the Genomics and Bioinformatics department, Institute of Molecular Genetics of the ASCR (Prague, Czechia). The procedure was carried out twice. Because of the limited resource only 6 properly isolated samples from striatum (from 3 METH and from 3 SAL rats) were examined to distinguish the mRNA expression level of 29489 genes by the microarray technique in the first trial. Also, because of the limited resource only 6 properly isolated samples from the hippocampus (from 3 METH and from 3 SAL rats) were examined to distinguish the mRNA expression level of 29489 genes by the microarray technique in the second trial. Results of both examinations were evaluated by LIMMA analysis in the Genomics and Bioinformatics department, Institute of Molecular Genetics of the ASCR (Prague, Czechia).

Real-Time PCR Technique {#S2.SS5}
-----------------------

Total RNA (70 ng) from 8 METH and 8 SAL rats was processed using TaqMan Gene Expression Assays (ThermoFisher Scientific, United States) and TaqMan Gene Expression Master Mix (ThermoFisher Scientific, United States) by real-time PCR in the 7500 Fast Real-Time PCR System (ThermoFisher Scientific, United States). Together 6 genes, Gapdh, Pgk1, 18sRNA, B2m, Rps6, PPIA ([@B8]; [@B53]; [@B123]; [@B115]; [@B75]; [@B46]) were assessed for their potential as being suitable reference genes in all three types of tissue. Reference genes, Rps6 and B2m were chosen according to the best reproducible results observed for gene expression in all three of tissues (striatum, hippocampus, prefrontal cortex), and taking into account the published results of another scientific group ([@B123]). A quantification of gene expression was calculated by the Pfaffl method ([@B103]; [@B135]); exponential amplifications factors of Assays were equal to 1 (ThermoFisher Scientific, United States). Differences were counted by the Mann--Whitney *U*-test.

Gene Anthology {#S2.SS6}
--------------

The first group of genes ([Table 2](#T2){ref-type="table"}), which was examined using real-time PCR, includes Bdnf, nuclear receptor subfamily 3 group C member 1 (Nr3c1), Esr1, insulin-like growth factor I receptor (Igfr1), and olfactory factor 522 (Olr522). The genes were chosen based on data published by various scientific groups ([@B96]; [@B16]; [@B159]; [@B133]; [@B19]; [@B5]; [@B119], [@B120], [@B121]; [@B86]; [@B88], [@B87]; [@B77]; [@B134]; [@B111], [@B110]). The second group of genes ([Table 3](#T3){ref-type="table"}), which was examined using real-time PCR, includes Tacr3, dopamine receptor D3 (Drd3), Cartpt, Rps6ka a Foxp2 genes. The genes were chosen based on our results from the microarray technique and in accordance with data published by other scientific groups ([@B102]; [@B42]; [@B24]; [@B76]; [@B71]). Together, the expression of 10 genes was examined using the real-time PCR technique.

###### 

The first group of examined genes with the description of their function according to the NCBI gene database.

  **Gene**   **Name**                                          **Function (NCBI gene database)**                                                                                           **Published results of other scientific groups**
  ---------- ------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  OLR522     Olfactory receptor 522                            Interaction with odorant molecules in the nose; initiation of a neuronal response that triggers the perception of a smell   
  Bdnf       Brain-derived neurotrophic factor                 Plays a role in the development of hippocampal long term potentiation; involved in regulation of synaptic plasticity        Brain-derived neurotrophic factor is involved in the METH dependence ([@B111], [@B110]).
  Nr3c1      Nuclear receptor subfamily 3, group C, member 1   Glucocorticoid receptor that binds and activates hormone-dependent transcriptional enhancers                                Glucocorticoid receptors are involved in METH-induced hyperactivity ([@B5]).
  Esr1       Estrogen receptor 1                               Acts as a transcriptional activator when bound to estrogen; may play a role in myocardial regulation                        The gene ESR1 may play a role in the pathophysiology of methamphetamine induced psychosis patients ([@B67])
  Igf1r      Insulin-like growth factor 1 receptor             Involved in induction of cell cycle progression and survival in many cell types                                             Insulin like growth factor binding protein 5 is involved in METH-induced apoptosis ([@B77]).

###### 

The second group of examined genes with the description of their function according to the NCBI gene database.

  **Gene**   **Name**                                                      **Function (NCBI gene database)**                                                                                                                     **Published results of other scientific groups**
  ---------- ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Foxp2      Forkhead box P2                                               Proper development of speech and language regions of the brain during embryogenesis                                                                   The Forkhead box P2 gene is a candidate to study cognitive functions ([@B42])
  Rps6ka3    Ribosomal protein S6 kinase A3                                Controlling cell growth and differentiation                                                                                                           
  Cartpt     Cocaine- and Amphetamine-Regulated Transcript prepropeptide   Neuronal protein that may play a role in brain development and may be regulated by testosterone                                                       An upregulation of Cartpt gene in the striatum of shock-resistant rats related to addiction to METH ([@B71])
  Tacr3      Tachykinin receptor 3                                         Receptor for tachykinin neuromedin K (neurokinin B); couples with G protein that activates the phosphatidylinositol-calcium second messenger system   The sequence variations in tachykinin receptor 3 are associated with alcohol and cocaine addiction ([@B40]).
  Drd3       Dopamine receptor D3                                          May be involved in facilitating the effects of antipsychotic drugs and drug treatments for Parkinson's disease                                        A single cocaine exposure increases Bdnf and D3 receptor expression ([@B76]).

Results {#S3}
=======

The weights of SAL animals ranged from 285 to 360 g with a median of 310,5 g. The weights of METH animals ranged from 298 to 350 g with the median of 330 g. The animals were divided into boxes of four (1--4, 5--8).

Results of Microarray Trials {#S3.SS1}
----------------------------

### Results of the First Microarray Trial in the Striatum {#S3.SS1.SSS1}

The mRNA expression (cDNA) of 29489 genes was examined in 6 striatum samples: three samples from the prenatally METH-exposed rats and three samples from the prenatally SAL-exposed rats. The expression of approximately 2189 genes was either up-regulated or down-regulated (*p* \< 0.05) in the striatum, however, the differences were very low. The borderline significant difference (*p* \< 0.05 and logFC \> 1) between METH and SAM samples was observed in the case of Drd3 and Tacr3 genes ([Table 4](#T4){ref-type="table"}) ([@B164]). The significant difference (*p* \< 0.05 and logFC \> 1) between METH and SAM samples was observed in the case of Cartpt gene, olfactory receptor 522 and 1448 genes ([Table 4](#T4){ref-type="table"}) ([@B164]). The non-significant difference between METH and SAM samples was observed in the case of Foxp2 and Rps6ka3 genes ([Table 4](#T4){ref-type="table"}) ([@B164]).

###### 

The most relevant results of the first microarray trial in the striatum.

  **Gene**   **GENENAME**                                                  **logFC**   ***p-*value**
  ---------- ------------------------------------------------------------- ----------- ---------------
  Olr522     Olfactory receptor 522                                        −1.45       4.9e-06
  Foxp2      Forkhead box P2                                               0.36        0.011
  Rps6ka3    Ribosomal protein S6 kinase polypeptide 3                     0.29        0.017
  Cartpt     Cocaine- and amphetamine-regulated transcript prepropeptide   1.09        0.0021
  Tacr3      Tachykinin receptor 3                                         0.88        0.00021
  Drd3       Dopamine receptor 3                                           0.94        0.00041
  Olr1448    Olfactory receptor 1448                                       −1.06       3.6e-05

### Results of the Second Microarray the Trial in the Hippocampus {#S3.SS1.SSS2}

The mRNA expression (cDNA) of 29489 genes was examined in 6 hippocampus samples: three samples from the prenatally METH-exposed rats and three samples from the prenatally SAL-exposed rats. The expression of approximately 1344 genes was either up-regulated or down-regulated (*p* \< 0.05) in the hippocampus, however, the differences were very low. The borderline significant difference (*p* \< 0.05 and logFC \> 1) between METH and SAM samples was observed in the case of Taar7h gene. The significant difference *(p* \< 0.05 and logFC \> 1) between METH and SAM samples was observed in the case of carboxylesterase 2i (Ces2) and olfactory receptor 1726 genes ([Table 5](#T5){ref-type="table"}). The non-significant difference between METH and SAM samples was observed in the case of Tacr3 gene ([@B165]).

###### 

The most relevant results of the second microarray trial in the hippocampus.

  **SYMBOL**   **GENENAME**                          **logFC**   ***p*-value**
  ------------ ------------------------------------- ----------- ---------------
  Ces2i        Carboxylesterase 2                    −1.04       0.006
  Olr1726      Olfactory receptor 1726               −1.17       0.0044
  Taar7h       Trace amine-associated receptor 7 h   0.82        0.00077
  Tacr3        Tachykinin receptor 3                 0.19        0.039

### Results of Real-Time PCR {#S3.SS1.SSS3}

For each of the tissue types (striatum, hippocampus and prefrontal cortex) the expression of chosen genes was examined using real-time PCR with TaqMan^®^ Gene Expression Assays (ThermoFisher Scientific, United States). The measured values were normalized to the measured values of two reference genes, B2m and Rps6, and quantified by the Pfaffl method (calculation of ratio of target to reference gene). Significant differences between METH and SAM samples were evaluated by the Mann--Whitney *U*-test ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}).

### Results of Real-Time PCR in the Prefrontal Cortex {#S3.SS1.SSS4}

In the prefrontal cortex of prenatally METH-exposed rats, the mRNA expression of the Nr3c1 gene was significantly (*p* ≤ 0.01) increased compared to that in prenatally SAL-exposed rats ([Figure 1](#F1){ref-type="fig"}). The measured values were normalized to the measured values of the reference B2m gene. However, the increase was not detected, when the measured values were normalized to the measured values of the reference Rps6 gene. The mRNA expression of the Foxp2 gene of prenatally METH-exposed rats was significantly (*p* ≤ 0.05) decreased compared to that in prenatally SAL-exposed rats in the prefrontal cortex, when the measured values were normalized to the measured values of the reference Rps6 gene. However, no difference was observed, when the measured values were normalized to the measured values of the reference B2m gene.

![Significant difference (*p* ≤ 0.01) in the expression of Nr3c1 gene between METH and SAL samples in the prefrontal cortex. The results of the Nr3c1 gene expression were normalized to the results of the expression of the reference B2m gene. The values of METH rats are marked as M and the values of SAL rats are marked as S. The values are presented with a median. The number of values is higher than 8 M and 8 S, respectively 8 METH and 8 SAL, because we also used the remaining samples from the pilot study (S1--S3, M1--M5).](fnins-13-00771-g001){#F1}

### Results of Real-Time PCR in the Striatum {#S3.SS1.SSS5}

In the striatum of prenatally METH-exposed rats, the mRNA expression of Tacr3 gene (*p* \< 0.01) and dopamine receptor D3 gene (*p* \< 0.05) were significantly increased compared to that in prenatally SAL-exposed rats. The measured values were normalized to the measured values of the reference B2m gene ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). No increase however was observed, when the measured values were normalized to the measured values of the reference Rps6 gene.

![Significant difference (*p* ≤ 0.01) in the expression of the Tacr3 gene between METH and SAL samples in the striatum. The results of the Tacr3 gene expression were normalized to the results of the expression of the reference B2m gene. The values of METH rats are marked as M and the values of SAL rats are marked as S. The values are presented with a median.](fnins-13-00771-g002){#F2}

![Significant difference (*p* ≤ 0.05) in the expression of the dopamine D3 receptor (Drd3) gene between METH and SAL samples in the striatum. The results of the Drd3 gene expression were normalized to the results of the expression of the reference B2m gene. The values of METH rats are marked as M and the values of SAL rats are marked as S. The values are presented with a median.](fnins-13-00771-g003){#F3}

### Results of Real-Time PCR in the Hippocampus {#S3.SS1.SSS6}

No differences in the mRNA expression were observed for any of the genes between prenatally METH-exposed rats and prenatally SAL-exposed rats in the hippocampus, even if the measured values were normalized to the measured values of either Rps6 or B2m reference genes.

Discussion {#S4}
==========

Using a real-time PCR technique we examined changes in gene expression in the striatum, hippocampus, and prefrontal cortex. Using microarray we examined the changes in gene expression in the striatum and hippocampus of prenatally METH-exposed rats. Despite our expectations, we found only three genes in the striatum from approximately 2189 up-regulated or down-regulated genes, and found only two genes in the hippocampus from approximately 1344 up-regulated or down-regulated genes, whose mRNA expression were significantly altered (*p* \< 0.05 and logFC \> 1). In addition, according to our previous studies, particularly the striatum and hippocampus are structures that demonstrated the impairment associated with METH-induced behavioral changes ([@B12]; [@B39]; [@B41]). For that reason we did not perform the third microarray trial with the samples from the prefrontal cortex, where we did not expect many changes.

Olfactory Receptors {#S4.SS1}
-------------------

The microarray technique demonstrated significant decrease in the mRNA expression of the genes encoding the olfactory receptors 522 and 1448 in the striatum of prenatally METH-exposed rats. In the hippocampus of prenatally METH-exposed rats the microarray technique demonstrated significant decrease in the mRNA expression of the olfactory receptor 1726. Given that the olfactory receptors are only present in the Rattus norvegicus species (NCIB database) we did not further investigate the decreased mRNA of olfactory gene expression in the striatum and hippocampus, as such studies in rats would not contribute to our understanding of addiction to METH in humans.

Reference Genes {#S4.SS2}
---------------

Using real-time PCR 6 genes, Gapdh, Pgk1, 18sRNA, B2m, Rps6, and PPIA ([@B8]; [@B53]; [@B123]; [@B115]; [@B75]; [@B46]) were assessed for their potential as being suitable reference genes in all three types of tissue. Reference genes, Rps6 and B2m, were chosen according to the best reproducible results observed for gene expression in all three types of tissues (striatum, hippocampus, prefrontal cortex).

### Ribosomal Protein S6 {#S4.SS2.SSS1}

Ribosomal Protein S6 is a major substrate of protein kinases in eukaryotic ribosomes (NCBI gene database). Recent studies concluded that cellular Ser/Thr kinase mTOR1 activation and rpS6 phosphorylation interrelated ([@B150]; [@B58]). Activated mTORC1 complex initiates phosphorylation of rpS6 protein ([@B150]; [@B58]), and METH decreases phosphorylation of mTORC1 and its downstream kinases ([@B85]). mTOR activation in the complexes with proteins, subsequent activation/phosphorylation of down-stream substrates (RSP6 protein) and METH-induced suppression of mTOR1 phosphorylation was also demonstrated in the nucleus accumbens ([@B58]). In summary, mTORC1 regulates cell proliferation through Rps6 phosphorylation and METH decreases phosphorylation of mTORC1. Given that RPS6 is related to METH metabolism, the results of analyses, where RPS6 is used as a reference gene, are questionable. Of note, the gene encoding Rps6ka3, which is Rps6 kinase, polypeptide 3, was one of 29489 up-regulated genes in the striatum in the first microarray trial.

### Beta-2-Microglobulin {#S4.SS2.SSS2}

Beta-2-Microglobulin is a serum protein found in association with the major histocompatibility complex class I heavy chain on the surface of nearly all nucleated cells ([@B47]; NCBI gene database). No differences in the expression of the B2m gene were observed in the striatum or in the hippocampus during the microarray trials. The B2m gene was therefore considered to be a suitable reference gene for use in the real-time PCR studies, when examining all three types of tissues in the prenatally METH-exposed rats.

The previous studies demonstrated that prenatal METH exposure can impair the development of the neonatal central nervous system ([@B155]; [@B130]; [@B136]; [@B108]) and the developing brain seems to be one of the primary targets of developmental toxicities of amphetamine and methamphetamine ([@B144]; [@B86]). There was evidence of oxidative DNA damage in embryonic and fetal brains of mice caused by amphetamines ([@B65]; [@B158]). METH can be activated to free radical intermediates that initiate ROS formation and cause oxidative DNA damage in the brain ([@B63]; [@B158]; [@B64]; [@B109]). The damage leads to long-term postnatal neurodevelopmental deficits via a mechanism different from that underlying the neurodegeneration observed in METH-exposed adults ([@B65]).

Altered Gene Expression in the Striatum: Cartpt, Drd3, Tacr3 {#S4.SS3}
------------------------------------------------------------

Prenatal METH exposure induces abnormalities in the brain's structure and chemistry, especially in the striatum ([@B19]; [@B28]). [@B157] described regional dependent distribution of METH in pup brains on gestational day 14 with the highest concentration in the striatum ([@B157]; [@B108]). **Cart peptide** was detected in the rat nucleus accumbens and due to its distribution in the brain and its modulation of dopamine systems, may be involved in aspects of reward and drug abuse ([@B59]; [@B72]). In our project, the microarray technique demonstrated a significant increase in the mRNA expression level of the gene coding Cart prepropeptide in the striatum of prenatally METH-exposed rats. The differences in mRNA expression between prenatally METH-exposed and prenatally SAL-exposed rats using microarray were very low. It appears that the dose 5 mg/kg/day of METH administered to the mothers during the gestation period might be too low to cause strong significant impairment in the development of the striatum, hippocampus and prefrontal cortex of the offspring. This may be the reason why we did not detect significant differences in the Cartpt gene expression using real-time PCR technique. However, when comparing our results to those of older studies, it must be pointed out that also acute administration of methamphetamine increased Cartpt mRNA level in the nucleus accumbens ([@B100]; [@B118]; [@B62]; [@B114]). Kuhar and colleagues demonstrated that Cart peptides have a role in drug abuse by virtue of the fact that they are modulators of mesolimbic function ([@B72]). We can speculate that the mechanism of METH regulation of addiction is via the CREB phosphorylation pathway. METH self-administration causes enrichment of phosphorylated CREB (pCREB) ([@B70]) and CREB may activate Cartpt expression ([@B114]), and biologically active Cart peptide plays a role in reward and addiction ([@B33]; [@B43]).

It was previously reported that METH self-administration was associated with transcriptional changes in genes that regulate transcription, synaptic transmission, and synaptic plasticity in the dorsal striatum ([@B70]). These molecular changes are associated with the transition from recreational drug use to addiction ([@B149]; [@B70]). **Dopamine Receptor D3** has the highest binding affinity for endogenous dopamine of all known dopamine receptors ([@B138]; [@B99]) and shows preferential neuroanatomical localization in the limbic area ([@B11]; [@B79]; [@B78]; [@B29]; [@B99]). In our real-time PCR studies, the expression of the Drd3 gene in the striatum of METH exposed rats appeared to be significantly (*p* ≤ 0.05) increased compared to that in SAL exposed rats. Borderline significant increased mRNA expression of dopamine receptor D3 gene in the striatum was also observed in the first microarray study. [@B76] reported that a single administration of METH induces a transient increase in BDNF expression in the prefrontal cortex, associated with a long-lasting elevation in dopamine receptor D3 binding and mRNA levels in the nucleus accumbens ([@B76]; [@B137]). From cocaine use receptors D3 appeared to be up-regulated in the nucleus accumbens ([@B139]; [@B122]; [@B98]; [@B99]). Given that the effects of METH are believed to result primarily from the increased release of synthesized dopamine and inhibition of dopamine uptake ([@B99]; [@B22]) and that elevated extracellular concentrations of dopamine lead to increased stimulation of dopaminergic receptors ([@B113]; [@B104]; [@B108]) we could speculate that the basis of Drd3 contribution to the addiction to METH is in its sensitivity. A normalization of dopamine receptor D3 function may reduce vulnerability to relapse in psychostimulant abuse ([@B76]; [@B22]), and a blockade of the dopamine receptor D3 by an antagonist attenuated the incentive motivational effects of METH in rats and may have pharmacotherapeutic potential in the treatment of methamphetamine addiction ([@B50]; [@B22]). **Tachykinin Receptor 3 gene** (NK-3 receptor) expression was significantly (*p* ≤ 0.01) increased in the striatum of METH exposed rats compared to that in SAL exposed rats in our real-time PCR studies. Borderline significant increased mRNA expression of the Tacr3 gene in striatum was also detected in the microarrays trial. Of further note, we observed that the expression of the Tacr3 gene was also non-significantly up-regulated in METH hippocampus samples in our second microarray study. This result provides new evidence of METH and Tacr3 relation or interaction. The previous findings described the relation between METH neurotoxicity and neurokinin-1 (NK-1) receptor. The striatal neurokinin-1 receptors modulated METH-induced production of nitric oxide ([@B151]). METH induces pre- and post-synaptic damage in the striatum and can be prevented with pharmacological blockade of the NK-1 receptor ([@B163]; [@B146]). It was also previously reported that the NK-3 receptor (Tacr3) controls nucleus accumbens dopamine responses to cocaine in rats ([@B66]; [@B7]) and to alcohol in humans ([@B40]). In monkeys, repeated administration of cocaine induces a decrease in methylation of NK3 receptor gene ([@B27]; [@B124]) and the NK3 (Tacr3) antagonist blocks the behavioral effects of cocaine ([@B7]; [@B95]). We can speculate that prenatal METH exposure, like cocaine, decreases the methylation status of the Tacr3 gene and increases the expression of the Tacr3 gene within striatum of rats. If the pharmacological blockage of tachykinin receptors 1 and 3 prevents the METH effects in the striatum, the Tacr3 and its gene is a suitable target for studying the addiction to METH.

Altered Gene Expression in the Hippocampus: Ces2, Taar7h {#S4.SS4}
--------------------------------------------------------

Previous studies demonstrated that prenatal METH exposure may be neurotoxic to the developing brain; and prenatally METH-exposed children exhibited smaller hippocampus volumes compared with the control group correlated with poorer performance on sustained attention and delayed verbal memory ([@B20]). METH exposure early in life of mice caused sex- dependent impairments in object recognition, spatial learning, and memory in adulthood ([@B1]). In experimental rats, prenatal MA exposure caused an impairment of non-spatial memory ([@B134]). Our microarray technique detected significant differences in the expression of the Ces2 **gene** in the hippocampus of prenatally METH- and SAL-exposed rats. Ces2 is a member of a large multigene family. The enzymes encoded by these genes are responsible for the hydrolysis of ester- and amide-bond-containing drugs such as cocaine and heroin. They also hydrolyze long-chain fatty acid esters and thioesters ([@B80]; [@B34]; [@B44]; [@B153]). The products of hydrolysis are generally more polar than the original ester resulting in an increase in water solubility, promoting renal elimination ([@B74]). Mice and rats have plasma carboxylesterase activity, which scavenge many organophosphorus compounds, rendering animals more resistant to organophosphates ([@B32]; [@B89]). The human carboxylesterases are located in the cytoplasm and endoplasmic reticulum of numerous tissues, but the greatest quantities are found in the liver and small intestine where they contribute significantly to the first-pass metabolic hydrolysis of substrate drugs ([@B61], [@B60]; [@B116]; [@B143]; [@B48]; [@B74]). Our result provides evidence about prenatal METH-induced decrease in the expression of the Ces2 mRNA within the hippocampus of experimental rats. We suspect that the changes in the gene expression level in the hippocampus associated with addiction to METH would be more significant, if the prenatally METH-exposed experimental rats were subjected to stress-inducing conditions, such as social behavior, learning and memory tests. However, we can speculate that decreased expression of the Ces2 enzyme could contribute to such METH-induced impairment of hippocampus in rats. It is interesting to note that there is evidence of a clinically significant drug interaction of a carboxylesterase substrate and ethanol in humans. Ethanol-mediated inhibition of human Ces2 hydrolysis of cocaine was demonstrated in hepatic microsomes ([@B112]; [@B74]). The finding is an *in vitro* proof of an existence of metabolic process or signaling pathway, which could inhibit the function of Ces2 in mouse and human cells.

Our microarray technique detected up-regulated expression of Taar 7h gene in the hippocampus of prenatally METH-exposed rats. The specific function of Taar7h and other members of a family of Taars has not been determined yet ([@B117]). Taars are widely distributed throughout peripheral and brain tissues. Some Taars appear to be olfactory receptors, at least in rodents ([@B81]; [@B117]). The most effects have been reported on the Taar1 receptor. The previous experiments revealed Taar1 expression in many distinct rodent CNS regions, namely, nucleus accumbens/olfactory tubercle, as well as limbic and monoaminergic areas, such as hippocampus ([@B10]; [@B13]; [@B117]). Taar1 is a novel G protein-coupled receptor, which responds to a number of endogenous amines, as well as to number psychoactive drugs, i.e., amphetamines. Such sensitization effects of Taar1 to dopamine, serotonin and norepinephrine could account for its involvement in the rewarding effects of drugs of abuse. Accordingly, Taar1-knock out mice developed an earlier and longer-lasting methamphetamine induced conditioned place preference as compared to wild-type littermates ([@B2]; [@B117]). In addition, Taar1-knock out mice show increased locomotor response to amphetamine and, in the opposite case, the mice overexpressing Taar1 exhibited a lower response to the stimulating effects of amphetamine in terms of locomotor activity and monoamine release ([@B117]). These findings are important in the understanding of our result of the increased expression of Taar7 gene and of the previous finding that adult female rats in diestrus and adult males postnatally exposed to METH via breast milk had decreased locomotion and exploratory behavior ([@B56]).

Altered Expression in the Prefrontal Cortex: Foxp2, Nr3c1 {#S4.SS5}
---------------------------------------------------------

Previous studies reported the prenatal METH-induced impairment of prefrontal cortex in experimental rats ([@B41]; [@B54]) and in humans ([@B144]). [@B97] reported that patients addicted to methamphetamine exhibit impaired cognitive functions such as executive function, attention, social cognition, flexibility, and working memory ([@B97]). From our studies we found that the expression of the **Foxp2 gene** was significantly (*p* ≤ 0.05) changed using real-time PCR and non-significantly changed using microarray technique in the prefrontal cortex of prenatally METH-exposed rats compared to the gene expression in prefrontal cortex of prenatally SAL-exposed rats. The data from real-time technique were normalized to the expression of the reference Rps6 gene. Given the fact that RPS6 phosphorylation is related to the metabolism of methamphetamine, the result from real-time PCR is questionable. However, the function of the neural learning system is modulated in the case of Foxp2 mutation ([@B18]) and some cases of speech impairment were observed in prenatally METH-exposed children in some clinical trials ([@B16]; [@B159]).

In response to various stimuli, including stress, glucocorticoids coordinate metabolic, endocrine, immune, and nervous system responses ([@B84]; [@B145]). In the brain, the glucocorticoid receptor has been thought to modulate emotional behavior, cognitive functions, and addictive states ([@B145]). [@B84] studied neuroendocrine responses to stress in rats and observed that adult rats, the offspring of mothers that exhibited more licking and grooming of pups during the first 10 days of life, exhibited increased glucocorticoid receptor mRNA expression in the hippocampus ([@B84]). From our studies, no apparent significant increases in gene expression were observed in the hippocampus of prenatally METH-exposed rats. Our results from the real-time PCR trials demonstrated that the expression of the **Nr3c1 gene** was significantly (*p* ≤ 0.01) increased in the prefrontal cortex of prenatally METH-exposed rats compared to that in prenatally SAL-exposed rats. [@B17] and [@B152] studied neuroendocrine responses to stress and [@B68] studied neuroendocrine responses to childhood abuse and both confirmed that variations in the maternal behavior of pup-licking are associated with the methylation status of the Nr3c1 gene ([@B17]; [@B152]; [@B69]; [@B68]). Future research should examine if prenatal METH exposure is able to alter the methylation status of the Nr3c1 gene. However, our finding is in accordance with findings reported by other scientific groups, that an increased motor activity and declined adaptability ([@B96]), change of behavior in an unknown environment, and an improvement of cognitive functions and anxiety ([@B119], [@B120], [@B121]; [@B131]) are associated to METH in gestation. The glucocorticoid nuclear receptor Nr3c1 and its gene are suitable targets for studying the changes associated with addiction to METH.

The differences in the mRNA expression between prenatally METH-exposed and prenatally SAL-exposed rats using both techniques were very low. It appears that the dose 5 mg/kg/day of METH administered to the mothers during the gestation period might be too low to cause strong significant impairment in the development of the striatum, hippocampus and prefrontal cortex of the offspring. We have not demonstrated robust changes in the gene expression levels of prenatally METH-exposed rats. We isolated total RNA from adult rats on PD 80. It is possible that the changes in the gene expression just after birth could have been more robust since postnatally induced permanent behavioral changes have an impact on gene expression in the brain and can dramatically change prenatally adjusted a gene expression scenario that can disappear in adulthood.

Conclusion {#S5}
==========

The aims of our project were fulfilled. We have identified susceptible genes, candidates to the study of an impairment related to addiction to METH. Cartpt, Drd3, Tacr3 in the striatum and the Ces2 in the hippocampus have been found to be associated with addiction to METH. Future research should continue to confirm or refute our finding about an association between prenatal exposure to METH and the changes in the expression of Nr3c1 and Foxp2 genes in the prefrontal cortex. Further research is needed to confirm and investigate the novel finding of prenatally METH-induced decrease of Ces2 mRNA and prenatally METH-induced increase of Taar7h mRNA in the hippocampus. Our plan is to study the changes in the gene expression level in the striatum, hippocampus and prefrontal cortex of prenatally METH-exposed rats during the different stages of gestation. And in addition, we intend to study what genetic and epigenetic changes occur, when prenatally METH-exposed rats are subjected to varying stressful conditions.
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